Literature DB >> 32583396

Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer: a secondary analysis of the Japan Esophageal Cohort study.

Ichiro Oda1, Yuichi Shimizu2, Toshiyuki Yoshio3,4, Chikatoshi Katada5, Tetsuji Yokoyama6, Tomonori Yano7, Haruhisa Suzuki1, Satoshi Abiko8, Kenichi Takemura9, Tomoyuki Koike10, Kohei Takizawa11, Motohiro Hirao12, Hiroyuki Okada13, Takako Yoshii14, Atsushi Katagiri15, Takenori Yamanouchi16, Yasumasa Matsuo17, Hirofumi Kawakubo18, Nozomu Kobayashi19, Tadakazu Shimoda20, Atsushi Ochiai21, Hideki Ishikawa22, Akira Yokoyama23, Manabu Muto24.   

Abstract

BACKGROUND: Prospectively collected long-term data of patients undergoing endoscopic resection for superficial esophageal squamous cell carcinoma (ESCC) are limited. The aim of this study was to determine the prospectively collected long-term outcomes of endoscopic resection for ESCC as a secondary analysis of the Japan Esophageal Cohort (JEC) study.
METHODS: Patients who underwent endoscopic resection of intramucosal ESCC at 16 institutions between September 2005 and May 2010 were enrolled in the JEC study. All patients underwent endoscopic examination with iodine staining at 3 and 6 months after resection, and every 6 months thereafter. We investigated clinical courses after endoscopic resection, survival rates, and cumulative incidence of metachronous ESCC.
RESULTS: 330 patients (mean age 67.0 years) with 396 lesions (mean size 20.4 mm) were included in the analysis. Lesions were diagnosed as high-grade intraepithelial neoplasia in 17.4 % and as squamous cell carcinoma in 82.6 % (limited to epithelium in 28.4 %, to lamina propria in 55.4 %, and to muscularis mucosa in 16.2 %). En bloc resection was achieved in 291 (73.5 %). The median follow-up period was 49.4 months. Local recurrences occurred in 13 patients (3.9 %) and were treated by endoscopic procedures. Lymph node metastasis occurred in two patients (0.6 %) after endoscopic resection. The 5-year overall, disease-specific, and metastasis-free survival rates were 95.1 %, 99.1 %, and 94.6 %, respectively. The 5-year cumulative incidence rate of metachronous ESCC was 25.7 %.
CONCLUSIONS: Our study demonstrated that endoscopic resection is an effective treatment for intramucosal ESCC, with favorable long-term outcomes. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32583396     DOI: 10.1055/a-1185-9329

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  5 in total

Review 1.  Endoscopic resection for gastrointestinal tumors (esophageal, gastric, colorectal tumors): Japanese standard and future prospects.

Authors:  Yuka Yanai; Chizu Yokoi; Kazuhiro Watanabe; Naoki Akazawa; Junichi Akiyama
Journal:  Glob Health Med       Date:  2021-12-31

2.  Propensity-score matched analysis to evaluate efficacy of endoscopic submucosal dissection for superficial esophageal cancer in gastrectomized patients.

Authors:  Yasuhiko Hamada; Kyosuke Tanaka; Masaki Katsurahara; Noriyuki Horiki; Yuhei Umeda; Yohei Ikenoyama; Hiroki Yukimoto; Masahiko Tameda; Junya Tsuboi; Reiko Yamada; Misaki Nakamura; Hayato Nakagawa
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

Review 3.  Endoscopic Screening for Second Primary Tumors of the Esophagus Among Head and Neck Cancer Patients.

Authors:  Chen-Shuan Chung; Li-Jen Liao; Chia-Yun Wu; Wu-Chia Lo; Chen-Hsi Hsieh; Tzong-His Lee; Chao-Yu Liu; Deng-Yu Kuo; Pei-Wei Shueng
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 4.  Endoscopic resection of esophageal squamous cell carcinoma: Current indications and treatment outcomes.

Authors:  Seiichiro Abe; Yuichiro Hirai; Takeshi Uozumi; Mai Ego Makiguchi; Satoru Nonaka; Haruhisa Suzuki; Shigetaka Yoshinaga; Ichiro Oda; Yutaka Saito
Journal:  DEN open       Date:  2021-09-20

5.  Combination of Endoscopic Resection and Radiofrequency Ablation for the Treatment of Esophageal Squamous Cell Neoplasia With Multiple Lugol-Voiding Lesions.

Authors:  Zhihao Chen; Lizhou Dou; Yong Liu; Yueming Zhang; Shun He; Liyan Xue; Guiqi Wang
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.